|
|
Pilot Study of Intensification Chemotherapy With Interval-Compressed Vincristine, Topotecan Hydrochloride, and
Cyclophosphamide in Combination With A Standard Dose Interval-Compressed Chemotherapy Regimen Comprising Vincristine,
Doxorubicin Hydrochloride, Cyclophosphamide, Ifosfamide, and Etoposide in
Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
No phase specified | Treatment | Temporarily closed | Under 31 | COG-AEWS07P1 AEWS07P1, NCT00618813 |
Objectives Primary - To assess the feasibility and safety of adding interval-compressed vincristine, topotecan hydrochloride, and cyclophosphamide to a treatment protocol utilizing interval compression of vincristine,
doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide in patients with localized Ewing
sarcoma family of tumors.
Secondary - To estimate the event-free survival in patients treated with this regimen.
Entry Criteria Disease Characteristics:
- Diagnosis of extracranial Ewing sarcoma or peripheral primitive neuroectodermal tumor of bone or soft tissue
- Newly diagnosed disease
- Disease confirmed by biopsy only with no attempt at complete or partial resection
- Unplanned excision allowed provided adequate imaging was
obtained prior to surgery and incompletely resected disease is controlled by local therapy
- No esthesioneuroblastoma
- Localized disease, including any of the following sites:
- Chest wall tumors with ipsilateral pleural effusions, ipsilateral positive
pleural fluid cytology, or ipsilateral pleural based secondary tumor nodules
- No contralateral pleural effusions or pleural
nodules
- Regional lymph nodes that are clinically suspicious or confirmed by biopsy
- No distant lymph node metastases
- Extra-dural tumors arising in the bony skull
- No tumors arising in the intra-dural soft tissue or the intra-dural
region of the spine
- No evidence of metastatic disease, defined as any of the following:
- Lesions that are discontinuous from the
primary tumor
- Lesions that are not regional lymph nodes
- Lesions that do not share a body cavity with the primary tumor
- No evidence by CT scan of metastatic lung disease, defined as any of the following:
- One pulmonary nodule > 1 cm in diameter or more than one nodule > 0.5 cm diameter
- Pulmonary nodules that are resected and are not found to be metastatic Ewing sarcoma are allowed
- Biopsy proven solitary nodules measuring 0.5 to 1.0 cm or multiple nodules measuring 0.3 to 0.5 cm
- Solitary nodules measuring < 0.5 cm or multiple nodules measuring < 0.3 cm are allowed unless biopsy proven to be metastatic (biopsy is not required)
Prior/Concurrent Therapy:
- See Disease Characteristics
- No prior chemotherapy or radiotherapy
- No concurrent pegfilgrastim (Neulasta®) or sargramostim (GM-CSF)
- No other concurrent cancer chemotherapy or immunomodulating agents, including steroids, unless used as an
antiemetic
Patient Characteristics:
- Karnofsky performance status (PS) 0-2 (≥ 16 years old) OR Lansky PS 0-2 (< 16 years old)
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age/gender as follows:
- 1 month to < 6 months old (males and females 0.4 mg/dL)
- 6 months to < 1 year old (males and females 0.5 mg/dL)
- 1 to < 2 years old (males and females 0.6 mg/dL)
- 2 to < 6 years old (males and females 0.8 mg/dL)
- 6 to < 10 years old (males and females 1.0 mg/dL)
- 10 to < 13 years old (males and females 1.2 mg/dL)
- 13 to < 16 years old (males 1.5 mg/dL and females 1.4 mg/dL)
- ≥ 16 years old (males 1.7 mg/dL and females 1.4 mg/dL)
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
- AST or ALT < 2.5 times ULN for age
- Shortening fraction of ≥ 27% by ECHO or ejection fraction of ≥ 50% by radionuclide angiogram (MUGA)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Expected Enrollment 35Outcomes Primary Outcome(s)Incidence of death from complications during therapy or within one month of terminating therapy Incidence rate of dose-limiting toxicity during therapy Time from the start of
therapy to the initiation of local control measures planned for week 13 of therapy Evaluation of sustained compression Estimation of event-free survival Overall response
Outline This is a multicenter study. - Induction therapy (weeks 1-12): Patients receive vincristine IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11, and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 1 hour on days 1-5 in weeks 1 and 9 and on day 1 in weeks 5 and 11; ifosfamide IV over 1 hour on days 1-5 in weeks 3 and 7; etoposide IV over 1 hour on days 1-5 in weeks 3 and 7; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 5 and 11. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning 24-36 hours after the last dose of chemotherapy and continuing for at least 7
days or until blood counts recover, whichever comes last. Filgrastim is discontinued at least 24 hours prior to the next course of chemotherapy.
- Local control: Patients who respond to induction therapy may undergo surgery alone if the lesion can be resected with negative margins and with a reasonable functional result beginning in week 13. Following surgery, patients with unresectable lesions or inadequate margins may receive radiotherapy during week 15. Patients with bulky lesions in surgically difficult sites such
as the spine, skull, and periacetabular pelvis; poor response to induction chemotherapy; or
those in whom surgery would result in unacceptable functional results may receive radiotherapy alone in weeks 13-19. Patients with bulky lesions in difficult sites and who do not have a good clinical and radiographic response to induction therapy may receive radiotherapy to the primary site during weeks 13-19 followed by surgery of the involved site during week 25 after recovery from course 11 of chemotherapy. Patients with microscopic residual disease after planned pre-operative radiotherapy will receive
additional radiotherapy.
- Continuation therapy (weeks 15-36): Patients receive vincristine IV on day 1 in weeks 15, 16, 21-24, 27-30, 33, and 34; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 15, 21, and 29; cyclophosphamide IV over 1 hour on days 1-5 in weeks 15, 21 and 29 and on day 1 in weeks 23, 27, and 33; ifosfamide IV over 1 hour on days 1-5 in weeks 17, 19, 25, 31, and 35; etoposide IV over 1 hour on days 1-5 in weeks 17, 19, 25, 31, and 35; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 of weeks 23, 27, and 33. Patients also receive G-CSF SC as in induction therapy.
After completion of study treatment, patients are followed for 10 years.
Trial Contact Information
Trial Lead Organizations Children's Oncology Group | | | Leo Mascarenhas, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and
Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in
Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors | | Trial Start Date | | 2008-03-03 | | Trial Completion Date | | 2010-12-07 (estimated) | | Registered in ClinicalTrials.gov | | NCT00618813 | | Date Submitted to PDQ | | 2008-01-24 | | Information Last Verified | | 2009-05-13 | | NCI Grant/Contract Number | | CA98543 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|